PCAT19 and prostate carcinoma: PCAT19-long promoted prostate cancer progression by interacting with a nuclear riboprotein, Heterogeneous Nuclear Ribonucleoprotein A/B (HNRNPAB), to upregulate a subset of cell-cycle genes [63], suggesting a novel mechanism for the HNRNPAB role in prostate cancer progression.